Microbiome Therapies as an Emerging Therapeutic Approaches of Biomedicine: International Regulatory Approaches and Ethical Challenges
Drugs and Drug Candidates · 26.06.2026 · 5 (3) · 37
DOI: 10.3390/ddc5030037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs and Drug Candidates, online erschienen am 26.06.2026. Verfasst von Valentyn Shapovalov und 3 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Microbiome-oriented therapies, including fecal microbiota transplantation (FMT), phage therapy, and live biotherapeutic products (LBPs), represent a promising direction in modern biomedicine for addressing antimicrobial resistance (AMR), recurrent Clostridioides difficile infection (rCDI), and dysbiosis-associated conditions. Despite encouraging clinical outcomes, their integration into routine clinical practice remains limited due to regulatory heterogeneity and unresolved ethical challenges.
Objective
This review aims to analyze international regulatory approaches to microbiome-based therapies and to identify key bioethical issues associated with their clinical application. Main content: The paper summarizes current scientific evidence and regulatory frameworks governing microbiome therapies in the United States, the European Union, Ukraine, and selected Asia-Pacific countries. Particular attention is given to differences in classification, approval pathways, and safety requirements. The review also examines major ethical concerns, including informed consent, donor screening, biosafety, data protection, and equitable access to innovative treatments.
Conclusions
The analysis demonstrates that microbiome therapies have significant potential for improving clinical outcomes and supporting antimicrobial stewardship. However, their broader implementation requires the harmonization of regulatory frameworks, strengthening of biosafety standards, and development of clear ethical guidelines. International cooperation and accumulation of clinical evidence are essential for the safe and effective integration of microbiome-based interventions into healthcare systems.
Zitieren
APA
Shapovalov, V., Shapovalova, V., Osyntseva, A., & Shapovalov, V. (2026). Microbiome Therapies as an Emerging Therapeutic Approaches of Biomedicine: International Regulatory Approaches and Ethical Challenges. Drugs and Drug Candidates, 5(3), 37. https://doi.org/10.3390/ddc5030037
Vancouver
Shapovalov V, Shapovalova V, Osyntseva A, Shapovalov V. Microbiome Therapies as an Emerging Therapeutic Approaches of Biomedicine: International Regulatory Approaches and Ethical Challenges. Drugs and Drug Candidates. 2026;5(3):37. doi:10.3390/ddc5030037
BibTeX
@article{Shapovalov2026,
author = {Shapovalov, Valentyn and Shapovalova, Viktoriia and Osyntseva, Alina and Shapovalov, Valerii},
title = {Microbiome Therapies as an Emerging Therapeutic Approaches of Biomedicine: International Regulatory Approaches and Ethical Challenges},
journal = {Drugs and Drug Candidates},
year = {2026},
volume = {5},
number = {3},
pages = {37},
doi = {10.3390/ddc5030037}
}
EUVIMED